Descrizione

Lipidomic profiling of plasma and tissue samples from EPA versus DHA supplementation studies reveals distinct oxylipin and lipid mediator signatures.

Figure 33

Chart

Source Paper

Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete against Each Other?

Nutrients (2020)

PMID: 33276463

DOI: 10.3390/nu12123718

Cite This Figure

![Figure 33: Lipidomic profiling of plasma and tissue samples from EPA versus DHA supplementation studies reveals distinct oxylipin and lipid mediator signatures.]()

> Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." *Nutrients*, 2020. PMID: [33276463](https://pubmed.ncbi.nlm.nih.gov/33276463/)

<figure>
  <img src="" alt="Lipidomic profiling of plasma and tissue samples from EPA versus DHA supplementation studies reveals distinct oxylipin and lipid mediator signatures." />
  <figcaption>Figure 33. Lipidomic profiling of plasma and tissue samples from EPA versus DHA supplementation studies reveals distinct oxylipin and lipid mediator signatures.<br>  Source: Anandita Pal et al. "Do Eicosapentaenoic Acid and Docosahexaenoic Acid Have the Potential to Compete ." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33276463/">33276463</a></figcaption>
</figure>

Evidenze correlate

Omega-3 Fatty Acids (EPA/DHA) per Chronic Inflammation

Grado A · 30 studi